As per Attachment

Sanjivani Paranteral Ltd, a Mumbai-based pharmaceutical company making parenteral and oral solid products, announced its Q4 FY25 and full-year FY25 results. Q4 revenue from operations grew 41.3% year-on-year to INR 181.8 mn, with profit after tax (PAT) jumping 74.4% YoY to INR 21.9 mn. For the full year FY25, revenue rose 28.8% YoY to INR 701 mn and PAT grew 31.4% YoY to INR 81 mn, with EPS at INR 6.89 vs INR 5.28 in FY24. All three segments grew — injectables, oral solids, and nutraceuticals — with nutraceuticals surging 564% in FY25. Exports dominated the revenue mix at 81.5% for the full year, led by CIS/Russia, Middle East, Africa and Latin America markets.